The share price went to $10 on hopes of approval for CD12. Had we actually received approval I think we'd have been at like $15-20. If we get an EUA from Brazil and get the HIV BLA accepted that could be two approvals by sometime around spring 2022. I would think the share price would be around $30-35 at that point.

I would also think at that point that LH, NASH, and cancer trials would be moving faster since cash and personnel should no longer be in question which should also put upward pressure on the share price. If everything were to happen in our favor $50 seems attainable by this time next year. Things rarely go exactly the way you hope though.